Cyclin D1 Gene G870A Polymorphism Predicts Response to Neoadjuvant Radiotherapy and Prognosis in Rectal Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 68, Issue 4, 2007, Pages 1094-1101

  Ho Pun Cheung, Alexandre ^a,b   Assenat, Eric ^b   Thezenas, Simon ^b   Bibeau, Frédéric ^b   Rouanet, Philippe ^b   Azria, David ^a,b   Cellier, Dominic ^c   Grenier, Jean ^b   Ychou, Marc ^a,b   Senesse, Pierre ^b   Lopez Crapez, Evelyne ^b  

^a INSERM   (France)

^b CENTRE VAL D AURELLE   (France)

^c Direction des Affaires Médicales   (France)

Author keywords

Cyclin D1; Predictive marker; Radiotherapy; Rectal cancer; Single nucleotide polymorphism

Indexed keywords

PATHOLOGIC RESPONSES; PREDICTIVE MARKERS; RECTAL CANCER PATIENTS; SINGLE NUCLEOTIDE POLYMORPHISMS;

ONCOLOGY; PATHOLOGY; POLYMORPHISM; PROTEINS; RADIOTHERAPY; TUMORS;

GENES;

CYCLIN D1; NUCLEAR PROTEIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; EXON; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; RADIOSENSITIVITY; RECTUM CANCER; RECURRENT CANCER; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CYCLIN D1; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, BCL-1; GENETIC MARKERS; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, GENETIC; PROGNOSIS; RECTAL NEOPLASMS;

EID: 34447294560     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.01.022     Document Type: Article

References (48)

1. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336 (1997) 980-987
2. Camma C., Giunta M., Fiorica F., et al. Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. JAMA 284 (2000) 1008-1015
3. Kapiteijn E., Marijnen C.A., Nagtegaal I.D., et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345 (2001) 638-646
4. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet 358 (2001) 1291-1304
5. Sauer R. Adjuvant and neoadjuvant radiotherapy and concurrent radiochemotherapy for rectal cancer. Pathol Oncol Res 8 (2002) 7-17
6. Rouanet P., Fabre J.M., Dubois J.B., et al. Conservative surgery for low rectal carcinoma after high-dose radiation. Functional and oncologic results. Ann Surg 221 (1995) 67-73
7. Gerard J.P., Chapet O., Nemoz C., et al. Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: The lyon R96-02 randomized trial. J Clin Oncol 22 (2004) 2404-2409
8. Bouzourene H., Bosman F.T., Seelentag W., et al. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer 94 (2002) 1121-1130
9. Becouam Y., Blanc-Vincent M.P., Lasser P., et al. [Standards, options and recommendations for the management of patients with primary adenocarcinoma of the rectum. National Federation of Centers for the Fight against Cancer]. Presse Med 28 (1999) 1367-1374
10. Carles J., Monzo M., Amat M., et al. Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer. Int J Radiat Oncol Biol Phys 66 (2006) 1022-1030
11. Spindler K.L., Nielsen J.N., Lindebjerg J., et al. Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region. Int J Radiat Oncol Biol Phys 66 (2006) 500-504
12. Lievre A., Bachet J.B., Le Corre D., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66 (2006) 3992-3995
13. Sherr C.J. D-type cyclins. Trends Biochem Sci 20 (1995) 187-190
14. Coqueret O. Linking cyclins to transcriptional control. Gene 299 (2002) 35-55
15. Bartkova J., Lukas J., Strauss M., et al. Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 10 (1995) 775-778
16. Motokura T., and Arnold A. PRAD1/cyclin D1 proto-oncogene: Genomic organization, 5′ DNA sequence, and sequence of a tumor-specific rearrangement breakpoint. Genes Chromosomes Cancer 7 (1993) 89-95
17. Buckley M.F., Sweeney K.J., Hamilton J.A., et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene 8 (1993) 2127-2133
18. Maeda K., Chung Y., Kang S.M., et al. Cyclin D1 overexpression and prognosis in colorectal adenocarcinoma. Oncology 55 (1998) 145-151
19. Filmus J., Robles A.I., Shi W., et al. Induction of cyclin D1 overexpression by activated ras. Oncogene 9 (1994) 3627-3633
20. Quelle D.E., Ashmun R.A., Shurtleff S.A., et al. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 7 (1993) 1559-1571
21. Resnitzky D., Gossen M., Bujard H., et al. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 14 (1994) 1669-1679
22. Alt J.R., Cleveland J.L., Hannink M., et al. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev 14 (2000) 3102-3114
23. Benzeno S., and Diehl J.A. C-terminal sequences direct cyclin D1-CRM1 binding. J Biol Chem 279 (2004) 56061-56066
24. Lu F., Gladden A.B., and Diehl J.A. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res 63 (2003) 7056-7061
25. Solomon D.A., Wang Y., Fox S.R., et al. Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem 278 (2003) 30339-30347
26. Moreno-Bueno G., Rodriguez-Perales S., Sanchez-Estevez C., et al. Cyclin D1 gene (CCND1) mutations in endometrial cancer. Oncogene 22 (2003) 6115-6118
27. Benzeno S., Lu F., Guo M., et al. Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1. Oncogene 25 (2006) 6291-6303
28. Betticher D.C., Thatcher N., Altermatt H.J., et al. Alternate splicing produces a novel cyclin D1 transcript. Oncogene 11 (1995) 1005-1011
29. Knudsen K.E., Diehl J.A., Haiman C.A., et al. Cyclin D1: Polymorphism, aberrant splicing and cancer risk. Oncogene 25 (2006) 1620-1628
30. Dworak O., Keilholz L., and Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12 (1997) 19-23
31. Lewis R.C., Bostick R.M., Xie D., et al. Polymorphism of the cyclin D1 gene, CCND1, and risk for incident sporadic colorectal adenomas. Cancer Res 63 (2003) 8549-8553
32. Hofheinz R.D., Horisberger K., Woernle C., et al. Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer. Int J Radiat Oncol Biol Phys 66 (2006) 1384-1390
33. Arber N., Hibshoosh H., Moss S.F., et al. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 110 (1996) 669-674
34. Maeda K., Chung Y.S., Kang S.M., et al. Overexpression of cyclin D1 and p53 associated with disease recurrence in colorectal adenocarcinoma. Int J Cancer 74 (1997) 310-315
35. Akervall J., Kurnit D.M., Adams M., et al. Overexpression of cyclin D1 correlates with sensitivity to cisplatin in squamous cell carcinoma cell lines of the head and neck. Acta Otolaryngol 124 (2004) 851-857
36. Akervall J., Brun E., Dictor M., et al. Cyclin D1 overexpression versus response to induction chemotherapy in squamous cell carcinoma of the head and neck-preliminary report. Acta Oncol 40 (2001) 505-511
37. Stendahl M., Kronblad A., Ryden L., et al. Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer 90 (2004) 1942-1948
38. Ishii Y., Pirkmaier A., Alvarez J.V., et al. Cyclin d1 overexpression and response to bortezomib treatment in a breast cancer model. J Natl Cancer Inst 98 (2006) 1238-1247
39. Shintani S., Mihara M., Ueyama Y., et al. Cyclin D1 overexpression associates with radiosensitivity in oral squamous cell carcinoma. Int J Cancer 96 (2001) 159-165
40. Holley S.L., Parkes G., Matthias C., et al. Cyclin D1 polymorphism and expression in patients with squamous cell carcinoma of the head and neck. Am J Pathol 159 (2001) 1917-1924
41. Nakashima T., and Clayman G.L. Antisense inhibition of cyclin D1 in human head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 126 (2000) 957-961
42. Zhou P., Jiang W., Zhang Y.J., et al. Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene 11 (1995) 571-580
43. Yasui M., Yamamoto H., Ngan C.Y., et al. Antisense to cyclin D1 inhibits vascular endothelial growth factor-stimulated growth of vascular endothelial cells: Implication of tumor vascularization. Clin Cancer Res 12 (2006) 4720-4729
44. Liersch T., Langer C., Ghadimi B.M., et al. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy. J Clin Oncol 24 (2006) 4062-4068
45. Gordon M.A., Gil J., Lu B., et al. Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics 7 (2006) 67-88
46. Zhang W., Gordon M., Press O.A., et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenet Genomics 16 (2006) 475-483
47. Zwijsen R.M., Buckle R.S., Hijmans E.M., et al. Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev 12 (1998) 3488-3498
48. McMahon C., Suthiphongchai T., DiRenzo J., et al. P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. Proc Natl Acad Sci U S A 96 (1999) 5382-5387